Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABL1 | P00519 | 13/20 | 0.77 |
| ▸ | PDGFRA | P16234 | 10/20 | 0.77 |
| ▸ | BCR | P11274 | 7/20 | 0.77 |
| ▸ | PDGFRB | P09619 | 5/20 | 0.77 |
| ▸ | EGFR | P00533 | 1/20 | 0.77 |
| ▸ | PRKCA | P17252 | 1/20 | 0.77 |
| ▸ | KIT | P10721 | 5/20 | 0.71 |
| ▸ | KDR | P35968 | 2/20 | 0.70 |
| ▸ | PIKFYVE | Q9Y2I7 | 2/20 | 0.69 |
| ▸ | CSF1R | P07333 | 1/20 | 0.68 |
| ▸ | BRAF | P15056 | 1/20 | 0.68 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1415439 | 0.98 | ABL1 (0.74) | ABL1PDGFRABCRPDGFRBEGFR | |
| SCHEMBL1655072 | 0.93 | ABL1 (0.81) | ABL1PDGFRABCRPDGFRBEGFR | |
| SCHEMBL30899721 | 0.93 | ABL1 (0.67) | ABL1PDGFRABCRPDGFRBEGFR | |
| SCHEMBL2941693 | 0.93 | ABL1 (0.67) | ABL1PDGFRABCRPDGFRBEGFR | |
| SCHEMBL868006 | 0.93 | ABL1 (0.77) | ABL1PDGFRABCRPDGFRBEGFR | |
| SCHEMBL29441265 | 0.93 | ABL1 (0.77) | ABL1PDGFRABCRPDGFRBEGFR | |
| Hydrochloric Acid SCHEMBL868161 | 0.92 | ABL1 (0.76) | ABL1PDGFRABCRPDGFRBEGFR | |
| SCHEMBL2945359 | 0.92 | ABL1 (0.70) | ABL1PDGFRABCRPDGFRBEGFR | |
| SCHEMBL5185763 | 0.92 | ABL1 (0.83) | ABL1PDGFRABCRPDGFRBEGFR | |
| SCHEMBL1408876 | 0.92 | ABL1 (0.75) | ABL1PDGFRABCRPDGFRBEGFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1786799-B1 | NOVEL PHENYLAMINOPYRIMIDINE DERIVATIVES AS INHIBITORS OF BCR-ABL KINASE | NATCO PHARMA LTD (IN) | 2012-07-04 | — | — | EP | claimed |
| US-7910598-B2 | Condensing (3-trifluoromethylsulfonyl) benzoyl chloride and 4-methyl-2-nitro-aniline; reducing nitro group with stannous chloride; condensing amino group with cyanamide; cyclocondensing guanidine group with 3-dimethylamino-1-pyridin-3-yl-propenone; antiproliferative agents | NATCO PHARMA LIMITED (IN) | 2011-03-22 | — | — | US | claimed |
| US-9895367-B2 | Formulation comprising phenylaminopyrimidine derivative as active agent | NATCO PHARMA LIMITED (IN) | 2018-02-20 | — | — | US | disclosed |
| EP-2295424-B1 | Processes for the preparation of novel phenylaminopyrimidine derivatives as inhibitors of BCR-ABL kinase | NATCO PHARMA LTD (IN) | 2015-10-14 | — | — | EP | disclosed |
| EP-2683381-B1 | FORMULATION COMPRISING PHENYLAMINOPYRIMIDINE DERIVATIVE AS ACTIVE AGENT | NATCO PHARMA LTD (IN) | 2015-09-16 | — | — | EP | disclosed |
| EP-2683381-A1 | FORMULATION COMPRISING PHENYLAMINOPYRIMIDINE DERIVATIVE AS ACTIVE AGENT | Natco Pharma Limited (IN) | 2014-01-15 | — | — | EP | disclosed |
| US-20130338180-A1 | FORMULATION COMPRISING PHENYLAMINOPYRIMIDINE DERIVATIVE AS ACTIVE AGENT | NATCO PHARMA LIMITED (IN) | 2013-12-19 | — | — | US | disclosed |
| WO-2012120328-A1 | FORMULATION COMPRISING PHENYLAMINOPYRIMIDINE DERIVATIVE AS ACTIVE AGENT | NATCO PHARMA LIMITED (IN) | 2012-09-13 | — | — | WO | disclosed |
| EP-1786799-B1 | NOVEL PHENYLAMINOPYRIMIDINE DERIVATIVES AS INHIBITORS OF BCR-ABL KINASE | NATCO PHARMA LTD (IN) | 2012-07-04 | — | — | EP | disclosed |
| US-8183253-B2 | Condensing (3-trifluoromethylsulfonyl) benzoyl chloride and 4-methyl-2-nitro-aniline; reducing nitro group with stannous chloride; condensing amino group with cyanamide; cyclocondensing guanidine group with 3-dimethylamino-1-pyridin-3-yl-propenone; antiproliferative agents; chronic myeloid leukemia | NATCO PHARMA LIMITED (IN) | 2012-05-22 | — | — | US | disclosed |
| US-7910598-B2 | Condensing (3-trifluoromethylsulfonyl) benzoyl chloride and 4-methyl-2-nitro-aniline; reducing nitro group with stannous chloride; condensing amino group with cyanamide; cyclocondensing guanidine group with 3-dimethylamino-1-pyridin-3-yl-propenone; antiproliferative agents | NATCO PHARMA LIMITED (IN) | 2011-03-22 | — | — | US | disclosed |
| EP-2295424-A1 | Processes for the preparation of novel phenylaminopyrimidine derivatives as inhibitors of BCR-ABL kinase | Natco Pharma Limited (IN) | 2011-03-16 | — | — | EP | disclosed |
| US-20080306100-A1 | PHENYLAMINOPYRIMIDINE DERIVATIVES AS INHIBITORS OF BCR-ABL KINASE | NATCO PHARMA LIMITED (IN) | 2008-12-11 | — | — | US | disclosed |
| EP-1945222-A2 | PYRROLO[2,1-F] [1,2,4] TRIAZIN-4-YLAMINES IGF-1R KINASE INHIBITORS FOR THE TREATMENT OF CANCER AND OTHER HYPERPROLIFERATIVE DISEASES | Bayer HealthCare AG (DE) | 2008-07-23 | — | — | EP | disclosed |
| US-20070232633-A1 | Novel phenylaminopyrimidine derivatives as inhibitors of BCR-ABL kinase | NATCO PHARMA LIMITED (IN) | 2007-10-04 | — | — | US | disclosed |
| EP-1786799-A1 | NOVEL PHENYLAMINOPYRIMIDINE DERIVATIVES AS INHIBITORS OF BCR-ABL KINASE | Natco Pharma Limited (IN) | 2007-05-23 | — | — | EP | disclosed |
| WO-2007056170-A2 | PYRROLO[2,1-F] [1,2,4] TRIAZIN-4-YLAMINES IGF-1R KINASE INHIBITORS FOR THE TREATMENT OF CANCER AND OTHER HYPERPROLIFERATIVE DISEASES | BAYER HEALTHCARE AG (DE) | 2007-05-18 | — | — | WO | disclosed |
| WO-2006027795-A1 | NOVEL PHENYLAMINOPYRIMIDINE DERIVATIVES AS INHIBITORS OF BCR-ABL KINASE | NATCO PHARMA LIMITED (IN) | 2006-03-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130338180-A1 | FORMULATION COMPRISING PHENYLAMINOPYRIMIDINE DERIVATIVE AS ACTIVE AGENT | RET, ABL1, ERBB2 | ABL1 2/4885PDGFRA 84/4885BCR 6/4885 |
| US-20070232633-A1 | Novel phenylaminopyrimidine derivatives as inhibitors of BCR-ABL kinase | ABL1, ABL2, BCR | ABL1 1/4885PDGFRA 9/4885BCR 3/4885 |
| US-20080306100-A1 | PHENYLAMINOPYRIMIDINE DERIVATIVES AS INHIBITORS OF BCR-ABL KINASE | ABL1, ABL2, BCR | ABL1 1/4885PDGFRA 113/4885BCR 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.